Bernstein Adjusts Waters Price Target to $345 From $315, Maintains Market Perform Rating
Barclays Maintains Waters(WAT.US) With Sell Rating, Maintains Target Price $330
Waters Corp Is Maintained at Underweight by Barclays
Waters Analyst Ratings
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $330
Jefferies Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415
Upgrading Waters: A Buy Rating on LC Replacement Cycle and Strong Sector Positioning
Jefferies Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415
Waters Analyst Ratings
Waters Upgraded by Jefferies to Buy on Potential Super Cycle
Goldman Sachs Adjusts Price Target on Waters to $320 From $325, Maintains Neutral Rating
Jefferies Upgrades Waters(WAT.US) to Buy Rating, Raises Target Price to $415
Analysts Are Bullish on These Healthcare Stocks: Elanco Animal Health (ELAN), Waters (WAT)
Waters Analyst Ratings
Evercore ISI Adjusts Price Target on Waters to $355 From $335, Maintains In Line Rating
Analysts Offer Insights on Healthcare Companies: Waters (WAT), Neurocrine (NBIX) and Syndax Pharmaceuticals (SNDX)
Wells Fargo Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $380
Jefferies Upgrades Waters(WAT.US) to Buy Rating, Raises Target Price to $380
Waters Corp Initiated at Overweight by Wells Fargo
Waters Analyst Ratings